Abattis engages British Columbia Institute of Technology to study
growth rates and compounds in spinach
VANCOUVER, Feb. 4, 2013 /PRNewswire/ - Abattis Bioceuticals
Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU),
announces the engagement of BCIT to study the growth rates and
novel compounds present in baby spinach.
Mr. Mike Withrow, Chief Executive
Officer on behalf of the Company, stated, "We are pleased to start
on this project as it will substantiate the Vertical Automated Grow
System (VAGS) acquired from Vertical Designs Ltd. and serve as a
benchmark for growing, processing and the proprietary extraction of
botanicals under strict Standard Operating Protocols to achieve
pharmaceutical grade products." Mr. Withrow went on to state,
"This is our first step toward producing bio-pharma grade
botanicals that are standardized to targeted phytochemicals."
Dr. Paula N. Brown, Director of
Applied Research for BCIT's Natural Health & Food Products
Research Group, stated, "The proposed research project focuses on
the controlled and sustainable production of plants to meet the
demand for a traceable and consistent supply of botanical materials
for development of biopharmaceuticals." Under the direction
of Dr. Brown, BCIT has worked with the natural health product
sector for over a decade conducting applied research, including
product development, establishment of quality standards and
regulatory compliance. By providing fundamental investigations on
product quality, safety and efficacy, BCIT supports industry
through the entire continuum, from grower to manufacturer, ensuring
product integrity is maintained. "We are excited to be working with
this group", continued Dr. Brown, "as the expertise and technology
afforded by the combination of the VAGS and Abattis could serve as
a model for development of value-added products and potential
therapeutics from a wide variety of medicinal plants.
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company
with capabilities through its wholly owned subsidiaries of
producing, licensing and marketing proprietary ingredients and
bio-similar compounds for use in Pharmaceuticals, Nutraceutical,
Cosmetic and Animal Nutrition markets. The company also has a deep
pipeline of proprietary products ready for sale in high growth
areas of Functional Foods and Supplements business. For more
information, visit the Company's website at www.abattis.com.
About BCIT
http://www.bcit.ca/appliedresearch/nrg/
ON BEHALF OF THE BOARD
'Mike Withrow'
Michael Withrow, President &
CEO
Neither the CNSX Exchange nor its regulations
services accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Abattis Bioceuticals Corp.
